{
    "xml": "<topic id=\"PHP5475\" outputclass=\"drug\" rev=\"1.18\" type=\"drug\" namespace=\"/drugs/ipilimumab\" basename=\"ipilimumab\" title=\"IPILIMUMAB\">\n<title>IPILIMUMAB</title>\n<body>\r\n<p outputclass=\"interactionsLinks\"> List of individual interactants: <xref format=\"dita\" href=\"#bnf_int_1263\" namespace=\"/interactions/list-of-drug-interactions/cytotoxics/monoclonal-antibodies/ipilimumab\">Ipilimumab</xref>\n</p>\n<data name=\"vtmid\">704649006</data>\n<data name=\"classifications\">\n<data name=\"classification\">\n<data name=\"drugClassification\">\n<xref format=\"dita\" scope=\"local\" type=\"drugClassification\" href=\"#_872447286\" title=\"Monoclonal antibodies (antineoplastic)\">Monoclonal antibodies (antineoplastic)</xref>\n</data>\n</data>\n</data>\n<data name=\"primaryDomainOfEffect\">\n<data name=\"domainOfEffect\">  </data>\n</data>\r\n</body>\n<topic id=\"PHP39817\" outputclass=\"drugAction\" rev=\"1.5\" parent=\"/drugs/ipilimumab\">\n<title>Drug action</title>\n<body>\n<section>\n<sectiondiv>\n<p>Ipilimumab causes T-cell activation.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP39787\" outputclass=\"indicationsAndDose\" rev=\"1.23\" parent=\"/drugs/ipilimumab\">\n<title>Indications and dose</title>\n<body>\n<section outputclass=\"indicationAndDoseGroup\">\n<sectiondiv outputclass=\"therapeuticIndications\">\n<p outputclass=\"therapeuticIndication\">Treatment of unresectable or metastatic advanced melanoma</p>\n</sectiondiv>\n<p outputclass=\"routesOfAdministration\">By intravenous infusion</p>\n<ul outputclass=\"patientGroups\">\n<li outputclass=\"patientGroup adult\">\n<p>Adult</p>\n<p>(consult product literature).</p>\n</li>\n</ul>\n</section>\n</body>\n</topic>\n<topic id=\"PHP39844\" outputclass=\"cautions\" rev=\"1.8\" parent=\"/drugs/ipilimumab\">\n<title>Cautions</title>\n<body>\n<section outputclass=\"importantAdvice\">\n<title>Cautions, further information</title>\n<sectiondiv>\n<p>For full details consult product literature.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP39781\" outputclass=\"interactions\" rev=\"1.8\" parent=\"/drugs/ipilimumab\">\n<title>Interactions</title>\n<body>\n<section outputclass=\"general\">\n<sectiondiv>\n<p>Appendix 1 (ipilimumab).</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP39751\" outputclass=\"sideEffects\" rev=\"1.17\" parent=\"/drugs/ipilimumab\">\n<title>Side-effects</title>\n<body>\n<section outputclass=\"generalSideEffects\">\n<sectiondiv outputclass=\"frequencies\">\n<sectiondiv outputclass=\"notKnown\">\n<p outputclass=\"title\">Frequency not known</p>\n<p outputclass=\"sideEffects\">\n<ph outputclass=\"sideEffect\">Infusion-related side-effects</ph>\n</p>\n</sectiondiv>\n</sectiondiv>\n</section>\n<section outputclass=\"sideEffectsAdvice\">\n<title>Side-effects, further information</title>\n<sectiondiv>\n<p>For further information on side-effects, (including monitoring and management of side effects) consult product literature.</p>\n</sectiondiv>\n<sectiondiv>\n<p outputclass=\"title\">Immune-related reactions</p>\n<p>A corticosteroid can be used after starting ipilimumab, to treat immune-related reactions.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP39832\" outputclass=\"conceptionAndContraception\" parent=\"/drugs/ipilimumab\">\n<title>Conception and contraception</title>\n<body>\n<section outputclass=\"generalInformation\">\n<sectiondiv>\n<p>Use effective contraception.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP39777\" outputclass=\"pregnancy\" parent=\"/drugs/ipilimumab\">\n<title>Pregnancy</title>\n<body>\n<section outputclass=\"generalInformation\">\n<sectiondiv>\n<p>Avoid unless potential benefit outweighs risk (toxicity in <i>animal</i> studies).</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP39848\" outputclass=\"breastFeeding\" parent=\"/drugs/ipilimumab\">\n<title>Breast feeding</title>\n<body>\n<section outputclass=\"generalInformation\">\n<sectiondiv>\n<p>Discontinue breast-feeding&#8212;no information available.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP39799\" outputclass=\"hepaticImpairment\" parent=\"/drugs/ipilimumab\">\n<title>Hepatic impairment</title>\n<body>\n<section outputclass=\"generalInformation\">\n<sectiondiv>\n<p>Use with caution if plasma-bilirubin concentration greater than 3 times upper limit of normal range <i>or</i> if plasma-transaminase concentration 5 times or greater than the upper limit of normal range.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP39723\" outputclass=\"monitoringRequirements\" parent=\"/drugs/ipilimumab\">\n<title>Monitoring requirements</title>\n<body>\n<section outputclass=\"monitoringOfPatientParameters\">\n<sectiondiv>\n<p>For information on monitoring of side effects, consult product literature.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP59908\" outputclass=\"prescribingAndDispensingInformation\" rev=\"1.8\" parent=\"/drugs/ipilimumab\">\n<title>Prescribing and dispensing information</title>\n<body>\n<section>\n<sectiondiv>\n<p>Infusion-related side-effects have been reported; premedication with paracetamol and an antihistamine is recommended.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP39689\" outputclass=\"nationalFunding\" rev=\"1.24\" parent=\"/drugs/ipilimumab\">\n<title>National funding/access decisions</title>\n<body>\r\n<section>\r\n<sectiondiv outputclass=\"niceTechnologyAppraisals\">\r\n<p outputclass=\"title\">NICE technology appraisals (TAs)</p>\r\n<sectiondiv outputclass=\"niceTechnologyAppraisal\">\r\n<p outputclass=\"fundingIdentifier\">NICE TA268</p>\r\n<sectiondiv>\r\n<p outputclass=\"title\">Ipilimumab for previously treated advanced (unresectable or metastatic) melanoma (December 2012)</p>\r\n<p>Ipilimumab is recommended as an option for the treatment of advanced (unresectable or metastatic) melanoma in patients who have received prior therapy, only if the manufacturer provides ipilimumab with the discount agreed in the patient access scheme.</p>\n</sectiondiv>\n<xref format=\"html\" href=\"http://www.nice.org.uk/TA268\">www.nice.org.uk/TA268</xref>\n</sectiondiv>\r\n<sectiondiv outputclass=\"niceTechnologyAppraisal\">\r\n<p outputclass=\"fundingIdentifier\">NICE TA319</p>\r\n<sectiondiv>\r\n<p outputclass=\"title\">Ipilimumab for previously untreated advanced (unresectable or metastatic) melanoma (July 2014)</p>\r\n<p>Ipilimumab is recommended, within its marketing authorisation, as an option for treating adults with previously untreated advanced (unresectable or metastatic) melanoma, only if the manufacturer provides ipilimumab with the discount agreed in the patient access scheme.</p>\n</sectiondiv>\n<xref format=\"html\" href=\"http://www.nice.org.uk/TA319\">www.nice.org.uk/TA319</xref>\n</sectiondiv>\n</sectiondiv>\r\n<sectiondiv outputclass=\"smcDecisions\">\r\n<p outputclass=\"title\">Scottish Medicines Consortium (SMC) Decisions</p>\r\n<sectiondiv outputclass=\"smcDecision\">\r\n<sectiondiv>\r\n<p>The <i>Scottish Medicines Consortium</i> has advised (March 2013) that ipilimumab (<i>Yervoy</i>\r\n<tm tmtype=\"reg\"/>) is accepted for restricted use within NHS Scotland for the treatment of advanced (unresectable or metastatic) melanoma in adults who have received prior therapy, only whilst ipilimumab is available at the price agreed in the patient access scheme.</p>\n</sectiondiv>\n</sectiondiv>\n</sectiondiv>\n</section>\r\n\r\n</body>\n</topic>\n<topic id=\"PHP5475-medicinalForms\" outputclass=\"medicinalForms\" parent=\"/drugs/ipilimumab\">\n<title>Medicinal forms</title>\n<body>\n<section outputclass=\"licensingVariationStatement\">\n<p>There can be variation in the licensing of different medicines containing the same drug.</p>\n</section>\n</body>\n</topic>\n<parents>\n<xref format=\"dita\" scope=\"local\" type=\"drugs\" href=\"#drugs\" title=\"Drugs\" namespace=\"/drugs\">Drugs</xref>\n</parents>\n<children>\n<xref format=\"dita\" scope=\"local\" type=\"medicinalForm\" href=\"#PHP75772\" title=\"Solution for infusion\" namespace=\"/drugs/ipilimumab/solution-for-infusion\">Solution for infusion</xref>\n</children>\n<backlinks>\n<xref format=\"dita\" scope=\"local\" type=\"drugClassifications\" href=\"#PHP106980\" namespace=\"/drug-classifications\" title=\"Drug classifications\" count=\"1\" rel=\"backlink\">Drug classifications</xref>\n</backlinks>\n<links>\n<xref format=\"dita\" scope=\"local\" type=\"interaction\" href=\"#bnf_int_1263\" namespace=\"/interactions/list-of-drug-interactions/cytotoxics/monoclonal-antibodies/ipilimumab\" title=\"Ipilimumab\" count=\"1\" rel=\"link\">Ipilimumab</xref>\n<xref format=\"dita\" scope=\"local\" type=\"#drugs\" href=\"#drugs\" namespace=\"/drugs\" title=\"Drugs\" count=\"1\" rel=\"link\">Drugs</xref>\n<xref format=\"dita\" scope=\"local\" type=\"medicinalForm\" href=\"#PHP75772\" namespace=\"/drugs/ipilimumab/solution-for-infusion\" title=\"Solution for infusion\" count=\"1\" rel=\"link\">Solution for infusion</xref>\n</links>\n</topic>",
    "id": "PHP5475",
    "outputclass": "drug",
    "rev": "1.18",
    "type": "drug",
    "namespace": "/drugs/ipilimumab",
    "basename": "ipilimumab",
    "title": "IPILIMUMAB",
    "interactants": [
        {
            "id": "bnf_int_1263",
            "label": "Ipilimumab"
        }
    ],
    "vtmid": "704649006",
    "drugClassification": [
        "Monoclonal antibodies (antineoplastic)"
    ],
    "primaryDomainOfEffect": {
        "": {
            "domain": "",
            "therapeuticUses": {}
        }
    },
    "drugAction": {
        "drugAction": [
            {
                "type": "drugAction",
                "textContent": "Ipilimumab causes T-cell activation.",
                "html": "<p>Ipilimumab causes T-cell activation.</p>"
            }
        ]
    },
    "indicationsAndDoses": {
        "indicationAndDoseGroups": [
            {
                "indications": [
                    {
                        "textContent": "Treatment of unresectable or metastatic advanced melanoma",
                        "html": "Treatment of unresectable or metastatic advanced melanoma"
                    }
                ],
                "specificity": {
                    "routes": [
                        "intravenous infusion"
                    ],
                    "textContent": "By intravenous infusion",
                    "html": "By intravenous infusion"
                },
                "adult": [
                    {
                        "textContent": "(consult product literature).",
                        "html": "<p>(consult product literature).</p>"
                    }
                ]
            }
        ]
    },
    "cautions": {
        "importantAdvice": [
            {
                "type": "importantAdvice",
                "textContent": "For full details consult product literature.",
                "html": "<p>For full details consult product literature.</p>"
            }
        ]
    },
    "interactions": {
        "general": [
            {
                "type": "general",
                "textContent": "Appendix 1 (ipilimumab).",
                "html": "<p>Appendix 1 (ipilimumab).</p>"
            }
        ]
    },
    "sideEffects": {
        "general": {
            "frequencies": {
                "notKnown": [
                    {
                        "type": "notKnown",
                        "textContent": "Infusion-related side-effects",
                        "html": "Infusion-related side-effects",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    }
                ]
            }
        },
        "advice": [
            {
                "type": "advice",
                "textContent": "For further information on side-effects, (including monitoring and management of side effects) consult product literature.",
                "html": "<p>For further information on side-effects, (including monitoring and management of side effects) consult product literature.</p>"
            },
            {
                "type": "advice",
                "title": "Immune-related reactions",
                "textContent": "A corticosteroid can be used after starting ipilimumab, to treat immune-related reactions.",
                "html": "<p>A corticosteroid can be used after starting ipilimumab, to treat immune-related reactions.</p>"
            }
        ]
    },
    "conceptionAndContraception": {
        "generalInformation": [
            {
                "type": "generalInformation",
                "textContent": "Use effective contraception.",
                "html": "<p>Use effective contraception.</p>"
            }
        ]
    },
    "pregnancy": {
        "generalInformation": [
            {
                "type": "generalInformation",
                "textContent": "Avoid unless potential benefit outweighs risk (toxicity in animal studies).",
                "html": "<p>Avoid unless potential benefit outweighs risk (toxicity in <i>animal</i> studies).</p>"
            }
        ]
    },
    "breastFeeding": {
        "generalInformation": [
            {
                "type": "generalInformation",
                "textContent": "Discontinue breast-feeding&#8212;no information available.",
                "html": "<p>Discontinue breast-feeding&#8212;no information available.</p>"
            }
        ]
    },
    "hepaticImpairment": {
        "generalInformation": [
            {
                "type": "generalInformation",
                "textContent": "Use with caution if plasma-bilirubin concentration greater than 3 times upper limit of normal range or if plasma-transaminase concentration 5 times or greater than the upper limit of normal range.",
                "html": "<p>Use with caution if plasma-bilirubin concentration greater than 3 times upper limit of normal range <i>or</i> if plasma-transaminase concentration 5 times or greater than the upper limit of normal range.</p>"
            }
        ]
    },
    "monitoringRequirements": {
        "patientParameters": [
            {
                "type": "patientParameters",
                "textContent": "For information on monitoring of side effects, consult product literature.",
                "html": "<p>For information on monitoring of side effects, consult product literature.</p>"
            }
        ]
    },
    "prescribingAndDispensingInformation": {
        "prescribingAndDispensingInformation": [
            {
                "type": "prescribingAndDispensingInformation",
                "textContent": "Infusion-related side-effects have been reported; premedication with paracetamol and an antihistamine is recommended.",
                "html": "<p>Infusion-related side-effects have been reported; premedication with paracetamol and an antihistamine is recommended.</p>"
            }
        ]
    },
    "nationalFunding": {
        "niceTechnologyAppraisals": [
            {
                "type": "niceTechnologyAppraisals",
                "references": [
                    {
                        "id": "http://www.nice.org.uk/TA268",
                        "label": "www.nice.org.uk/TA268"
                    }
                ],
                "fundingIdentifier": "NICE TA268",
                "textContent": "Ipilimumab for previously treated advanced (unresectable or metastatic) melanoma (December 2012) Ipilimumab is recommended as an option for the treatment of advanced (unresectable or metastatic) melanoma in patients who have received prior therapy, only if the manufacturer provides ipilimumab with the discount agreed in the patient access scheme.\n\nwww.nice.org.uk/TA268",
                "html": "<p outputclass=\"title\">Ipilimumab for previously treated advanced (unresectable or metastatic) melanoma (December 2012)</p> <p>Ipilimumab is recommended as an option for the treatment of advanced (unresectable or metastatic) melanoma in patients who have received prior therapy, only if the manufacturer provides ipilimumab with the discount agreed in the patient access scheme.</p><xref format=\"html\" href=\"http://www.nice.org.uk/TA268\">www.nice.org.uk/TA268</xref>"
            },
            {
                "type": "niceTechnologyAppraisals",
                "references": [
                    {
                        "id": "http://www.nice.org.uk/TA319",
                        "label": "www.nice.org.uk/TA319"
                    }
                ],
                "fundingIdentifier": "NICE TA319",
                "textContent": "Ipilimumab for previously untreated advanced (unresectable or metastatic) melanoma (July 2014) Ipilimumab is recommended, within its marketing authorisation, as an option for treating adults with previously untreated advanced (unresectable or metastatic) melanoma, only if the manufacturer provides ipilimumab with the discount agreed in the patient access scheme.\n\nwww.nice.org.uk/TA319",
                "html": "<p outputclass=\"title\">Ipilimumab for previously untreated advanced (unresectable or metastatic) melanoma (July 2014)</p> <p>Ipilimumab is recommended, within its marketing authorisation, as an option for treating adults with previously untreated advanced (unresectable or metastatic) melanoma, only if the manufacturer provides ipilimumab with the discount agreed in the patient access scheme.</p><xref format=\"html\" href=\"http://www.nice.org.uk/TA319\">www.nice.org.uk/TA319</xref>"
            }
        ]
    },
    "medicinalForms": {
        "licensingVariationStatement": [
            {
                "type": "licensingVariationStatement",
                "textContent": "There can be variation in the licensing of different medicines containing the same drug.",
                "html": "<p>There can be variation in the licensing of different medicines containing the same drug.</p>"
            }
        ]
    },
    "children": {
        "medicinalForm": [
            {
                "id": "PHP75772",
                "label": "Solution for infusion",
                "type": "medicinalForm"
            }
        ]
    },
    "backlinks": {
        "drugClassifications": [
            {
                "id": "PHP106980",
                "label": "Drug classifications",
                "type": "drugClassifications"
            }
        ]
    },
    "links": {
        "interaction": [
            {
                "id": "bnf_int_1263",
                "label": "Ipilimumab",
                "type": "interaction"
            }
        ],
        "#drugs": [
            {
                "id": "drugs",
                "label": "Drugs",
                "type": "#drugs"
            }
        ],
        "medicinalForm": [
            {
                "id": "PHP75772",
                "label": "Solution for infusion",
                "type": "medicinalForm"
            }
        ]
    }
}